Research Article

DNA Binding and Antitumor Activity of α-Diimineplatinum(II) and Palladium(II) Dithiocarbamate Complexes

Hassan Mansouri-Torshizi,1 Maryam Saeidifar,2 Fatemeh Khosravi,1 Adeleh Divsalar,3 Ali Akbar Saboury,4 and Fatemeh Hassani1

1 Department of Chemistry, University of Sistan and Baluchestan, Zahedan 98167-45345, Iran
2 Nanotechnology and Advanced Materials Department, Materials and Energy Research Center, Karaj 31787-316, Iran
3 Department of Biological Sciences, Tarbiat Moallem University, Tehran 13145-1384, Iran
4 Institute of Biochemistry and Biophysics, University of Tehran, Tehran 13145-1384, Iran

Correspondence should be addressed to Hassan Mansouri-Torshizi, hmtorshizi@gmail.com

Received 23 May 2011; Accepted 25 July 2011

1. Introduction

In order to reduce the toxicity of cisplatin, that is, the well-known anticancer drug, and modulate its activity, a new strategy is the design of novel metal complexes containing N and S donor ligands [1–3]. This interest has probably initiated from detoxicant properties of sulfur-containing ligands against heavy metal intoxication [4]. As an example is the use of sodium diethyldithiocarbamate (DDTC) in the treatment of patients with acute poisoning of nickel carbonyl, arsenic, and thallium [5]. A further interest in this chelating ligand has arisen due to its highly selective use to protect a variety of animal species from renal, gastrointestinal, and bone marrow toxicity, induced by cisplatin without inhibition of cisplatin’s antitumor effect [6–9]. In addition, diethyldithiocarbamate has remarkable property of reversing platinum binding to macromolecules responsible for host toxicity. However, it does not interfere with the tumoricidal Pt-DNA interaction in the tumor cell. Thus, the protective action of the dithiocarbamate against the toxicity of cisplatin seems to be the formation of its stable platinum dithiocarbamate complexes [7, 10].

A large number of analogs of cisplatin have been tested, and it has been reported that many active complexes could react with cell DNA and inhibit its synthesis [11–14]. Recently, significant attention has been focused on the DNA binding properties of dithiocarbamate metal complexes [15–17] and several dithiocarbamate derivatives have been investigated as potential biologically active agents [18–23]. Among which platinum and palladium complexes of dithiocarbamates have gained considerable interest due-to-their potential antitumor properties [24–29].

It has also known that dithiocarbamate complexes of [M(NN)(SS)] type, with diimine (NN) as a π-electron acceptor and dithiocarbamate (SS) as an electron donor, exhibit intramolecular mixed metal ligand to ligand charge transfer bands [30, 31]. This band appears in a region where...
CT-DNA has no absorption and thus has been widely used for the absorption spectrophotometric binding studies.

In this work, we have chosen a bioactive octylthio-carbamate ligand whose structure not only resembles a great number of antibacterial, antiviral, anthelmintic, and insecticidal agent, but also can be used as inhibitor of cisplatin-induced nephrotoxicity [32] while as diimine we have employed 2,2′-bipyridine (bpy) whose structure adopts a planar conformation when it chelates to Pt(II) or Pd(II) center [33], and thus can intercalate in CT-DNA. These complexes have been tested against human cell tumor line K562. In order to confirm the mode of binding of these complexes to CT-DNA, detailed interaction studies of them with CT-DNA are attempted.

2. Experimental

2.1. Materials and Methods. Octylamine and carbon disulfide were purchased from Aldrich (England). Palladium(II) chloride was obtained from Fluka (Switzerland). Potassium tetrachloroplatinate, 2,2′-chloride was obtained from Fluka (Switzerland). Potassium fluoride were purchased from Aldrich (England). Palladium(II) of the absorbance at 260 to that of 280 nm check purity medium containing 20 mM NaCl. Monitoring the ratio 7.0 medium containing 20 mM NaCl. Monitoring the ratio 2.1. Materials and Methods.

Octylamine and carbon disulfide were purchased from Aldrich (England). Palladium(II) chloride was obtained from Fluka (Switzerland). Potassium tetrachloroplatinate, 2,2′-chloride, highly polymerized calf thymus DNA sodium salt, and Tris-HCl buffer were obtained from Merck (Germany). Other chemicals used were of analytical reagent or higher purity grade. [Pt(bpy)Cl2] and [Pd(bpy)Cl2] were prepared by the methods described in the literature [34]. Solvents used were of reagent grade and purified before use by the standard methods. All the experiments involving interaction of the complexes with CT-DNA were performed in Tris-HCl buffer (20 mM) of pH = 7.0 medium containing 20 mM NaCl. Monitoring the ratio of the absorbance at 260 to that of 280 nm checks purity of CT-DNA. The solution gave a ratio of >1.8 at A260/A280, indicating that CT-DNA is sufficiently free from protein [35, 36]. The CT-DNA concentration per nucleotide was determined by absorption spectroscopy using the known molar extinction coefficient value of 6600 M−1 cm−1 at 260 nm [37].

Electronic absorption spectra of the title metal complexes were measured on a JASCO UV/Vis-7850 recording spectrophotometer. Infrared spectra of the metal complexes were recorded on a JASCO-460 Plus FT-IR spectrophotometer in the range of 4000–400 cm−1 in KBr pellets. Microchemical analysis of carbon, hydrogen, and nitrogen for the complexes were carried out on a Heraeus CHNO-RAPID elemental analyzer. 1H NMR spectra were recorded on a Brucker DRX-500 Avance spectrometer at 500 MHz in DMSO-d6 using tetramethylsilane as internal reference. Fluorescence intensity measurements were carried out on a Hitachi spectrofluorimeter model MPF-4. Melting point was measured on a Unimelt capillary melting point apparatus and reported uncorrected. Conductivity measurements of the above platinum and palladium complexes were carried out on a Systronics conductivity bridge 305, using a conductivity cell of cell constant 1.0. Doubly distilled water was used as solvent all along.

2.2. Synthesis of Octylthiocarbamate Sodium Salt (Oct-dtcNa). This ligand was synthesized by the method as described earlier [15], except that butylamine was replaced by octylamine (8.33 mL, 50 mmol). The yield was 8.51 g (75%); m.p. 173°C. Anal. Calcd. For C19H26N4O3S2Pt (617): C, 36.95; H, 4.21; N, 9.08%. Found: C, 36.90; H, 7.93; N, 6.17%. Solid state IR spectroscopy of the above ligand shows three main characteristic bands at 1491, 930, and 2945 cm−1 assigned to v(N−C−S) and v(SCS) and v(N-H) stretching modes, respectively, [16]. 1H NMR (500 MHz, DMSO-d6, ppm, m = multiplet and s = singlet broad): 0.84 (m, 3H, H-a), 1.24 (m, 10H, H-b), 1.41 (m, 2H, H-c), 3.31 (m, 2H, H-d), and 7.98 (s, -NH−) (Scheme 1).

2.3. Synthesis of [Pt (Oct-dtc)/(bpy)]NO3. This complex was synthesized following our previous procedure [15], except that But-dtcNa was replaced by Oct-dtcNa. The yield was 0.475 g, 77% and the complex decomposes at 197°C. Analysis calculated for C19H26N4O3S2Pt (227 g/mol): C, 47.58; H, 7.93; N, 6.17%. Found: C, 47.64; H, 7.92; N, 6.16%. Solid state IR spectroscopy of the above ligand shows three main characteristic bands at 1491, 930, and 3171 cm−1 assigned to v(N−C−S) and v(SCS) and v(N-H) stretching modes, respectively, [16]. 1H NMR (500 MHz, DMSO-d6, ppm, m = multiplet and s = singlet broad): 0.84 (m, 3H, H-a), 1.24 (m, 10H, H-b), 1.41 (m, 2H, H-c), 3.31 (m, 2H, H-d), and 7.98 (s, -NH−) (Scheme 1). The sharp band at 1385 cm−1 is assigned to uncoordinated NO3− ion [39]. 1H NMR (500 MHz, DMSO-d6, ppm, Sb = singlet broad, t = triplet, d = doublet, q = quartet and m = multiplet [40]: 0.85 (t, 3H, H-a), 1.27 (m, 10H, H-b), 1.62 (t, 2H, H-c), 3.49 (t, 2H, H-d), 7.75 (t, 2H, H-4′), 8.45 (t, 2H, H-5′), 8.52 (q, 2H, H-3′), 8.70 (d, 2H, H-6′), and 11.53 (s, 1H, H-e), (Scheme 1). Molar conductance of the complex is 91.78 Ω−1 mol−1 cm2 indicating 1:1 electrolytes.
Electronic spectra exhibit five bands. The band at 364 (ε = 3.56) is assigned to MLCT and the other bands at 321 (ε = 6.72), 310 (ε = 5.42), 285 (ε = 13.69) and at 202 (ε = 27.41) may be due to first, second, and higher internal π-π* transitions of 2,2'-bipyridine as well as dithiocarbamate ligands [15].

2.4. Synthesis of [Pd(Oct-dtc)(bpy)]NO₃. This complex was prepared by a similar method to that of [Pt(bpy)(Oct-dtc)]NO₃. Yield was 0.360 g, 68% and decomposes at 178°C. Analysis calculated for C₁₉H₂₆N₄O₃S₂Pd (528): C, 43.18; H, 4.92; N, 10.61%. Found: C, 43.17; H, 4.93; N, 10.60%. Solid state FT-IR spectroscopy of the complex shows three characteristic stretching bands at 1539, 1030, and 2987 cm⁻¹ assigned to ν(N-CSS), ν(SCS), and ν(N-H) modes, respectively, [20, 38]. The sharp band at 1385 cm⁻¹ is assigned to uncoordinated NO₃⁻ ion [39]. ¹H NMR (500 MHz, DMSO-d₆, ppm, sb = singlet broad, t = triplet, q = quartet, and m = multiplet sb = 40): 0.82 (t, 3H, H-a), 1.24 (m, 10H, H-b), 1.57 (m, 2H, H-c), 4.45 (t, 2H, H-d), 7.69 (m, 2H, H-4,4'), 8.15 (q, 2H, H-5,5'), 8.26 (m, 2H, H-3,3'), 8.51 (q, 2H, H-6,6'), and 11.21 (sb, 1H, H-e) (Scheme 1). Molar conductance of the complex is 97 Ω⁻¹ mol⁻¹ cm² indicating 1:1 electrolytes [41]. Electronic spectra exhibit four bands. The bands at 318 (ε = 1.88) and 307 (ε = 1.82) are assigned to MLCT, and the other bands at 247 (ε = 6.50) and 203 (ε = 3.78) may be assigned to first and second intraligand π-π* transition of 2,2'-bipyridine ligand as well as −CSS− group of dithiocarbamate ligand [15].

2.5. Cytotoxic Studies. The procedure for cytotoxic studies of the [Pt(bpy)(Oct-dtc)]NO₃ and [Pd(bpy)(Oct-dtc)]NO₃ was similar to that reported earlier [15]. Here, also 1 × 10⁴ cells per mL of K562 chronic myelogenous leukemia were used in Tris-HCl buffer solution of PH 7.0.

2.6. Metal Complexes—DNA-Binding Studies. [Pt/Pd(bpy) (Oct-dtc)]NO₃ complexes were interacted with calf thymus DNA in Tris-HCl buffer (20 mM, PH = 7.0) containing 20 mM sodium chloride. The procedure followed to determine binding and thermodynamic parameters were similar to what was reported earlier [16]. The stock solutions of the complexes (0.5 mmol/L) and CT-DNA (4 mg/mL) were made in the same buffer. The DNA-metal complex solutions were incubated at 300 K and 310 K, and then, the spectrophotometric reading at λ_max of the complexes (321 nm for Pt(II) complex and 305 nm for pd(II) complex), where CT-DNA has no absorption, were measured. Using trial and error method, the incubation time for solutions of DNA-metal complexes at 300 K and 310 K was found to be 6 h. No further changes were observed in the absorbance reading after longer incubation. All the experiments repeated to get the constant results.

3. Results and Discussion

The compounds correspond to the composition Oct-dtcNa, [Pd(bpy)(Oct-dtc)]NO₃ and [Pt(bpy)(Oct-dtc)]NO₃, where bpy = 2,2'-bipyridine, and Oct-dtc = octyldithiocarbamato ligands were prepared and characterized by chemical analysis, conductance measurements, ultraviolet-visible, infrared and, ¹H NMR spectroscopic methods. These analytical data of the complexes are given in experimental section and the proposed structure in Scheme 1. Cytotoxicity and detailed calf thymus DNA-binding studies of these water-soluble complexes have been studied.

3.1. Cytotoxic Measurement of the Metal Complexes. [Pt/Pd (bpy)(Oct-dtc)]NO₃ complexes were screened for their antitumor activities against K562 chronic myelogenous leukemia cells [15]. These cells were maintained in RPMI 1640 medium supplemented with 10% FCS in a humidified incubator (310 K and 5% CO₂). The cells were then grown in RPMI medium supplemented with L-glutamine (2 mM), streptomycin and penicillin (5 μg/mL), and 10% heat-inactivated fetal calf serum, at 310 K under a 5% CO₂/95% air atmosphere. In this study, the harvested cells were seeded into 96-well plate (1 × 10⁴ cell/mL) with various concentrations of metal complexes ranging from 0 to 0.25 mM and incubated for 24 h [42]. The 50% cytotoxic concentrations (IC₅₀) of the Pt(II) and Pd(II) complexes were determined to be 0.0017 and 0.007 mM, respectively (Figure 1 for pt(II) complex and the inset for Pd(II) complex). As shown in Figure 1, cell growing after 24 h was significantly reduced in the presence of various concentrations of the metal complexes. Furthermore, IC₅₀ value of cisplatin under the same experimental conditions was determined. This value (0.154 mM) is much higher as compared to the IC₅₀ value of the above two complexes. However, the IC₅₀ values of these complexes are comparable with those of our analogous Pt(II) and Pd(II) dithiocarbamate complexes reported earlier [15–17]. This procedure for growth inhibition studies of the metal complexes established that the cell DNA is the target biomolecule for these complexes [39].

3.2. DNA-Binding Studies

3.2.1. CT-DNA Denaturation Data and Evaluation of Thermodynamic Parameters. Absorption spectroscopy is one of the most useful techniques to study the binding of any drug to DNA [43–46]. The procedure followed was similar to that reported earlier [47, 48]. These experiments were carried out separately at two temperatures of 300 K and 310 K in Tris-HCl buffer medium. The absorbance at 260 nm was monitored for either CT-DNA (0.129 mM and 0.115 mM for experiments carried out for Pt(II) complex and 0.197 mM and 0.187 mM for Pd(II) complex at 300 K and 310 K, resp.) or mixtures of CT-DNA with increasing concentrations of Pt(II) and Pd(II) complexes (0.0028 mM to 0.00130 mM and 0.0028 mM to 0.114 mM for Pt(II) complex and 0.0068 mM to 0.140 mM and 0.0028 mM to 0.113 mM for Pd(II) complex at 300 K and 310 K, resp.). Also the absorbance of CT-DNA and mixture of DNA-Pt(II)/Pd(II) complexes was measured at 640 nm to eliminate the interference of turbidity.

The profiles of denaturation of CT-DNA by [Pt(Oct-dtc)(bpy)]NO₃ and [Pd(Oct-dtc)(bpy)]NO₃ are shown in
features of 300 K and 310 K.

Due to increasing the total concentration of 
\([\text{Pt(bpy)(Oct-dtc)}]\NO_3\]
and the inset for 
\([\text{Pd(bpy)(Oct-dtc)}]\NO_3\],
Figure 2: The changes of absorbance of CT-DNA at 260 nm due to increasing the total concentration of [Pt(bpy)(Oct-dtc)]NO₃ and the inset for Pd(II) complex on K562 cell line assessed using MTT assay as described in Section 2.1. The tumor cells were incubated with varying concentrations of the complexes for 24 h.

It is noticeable that absorbance of DNA at 260 nm should increase in presence of increasing amount of each metal complex (denaturant agent). This is true for palladium complex (Figure 2). However, the opposite trend is observed for the platinum analog. Keeping in mind that platinum complexes react about 10⁶–10⁷ times slower than palladium complexes [49, 50], the decrease in the absorbance at 260 nm with the increase of the amount of Pt(II) complex added to CT-DNA may be due to (i) a possibility that interaction between CT-DNA and the metal complex causes the double helix of CT-DNA to become more straight leading to stacking; this stacking may cause conformational changes leading to a sort of denaturation or (ii) each strand after denaturation gets associated in a more stacked structure and (iii) metal complex slips into the helix and masks the hydrophobic bases leading to a decrease in absorbance. As will be seen in the later part of this paper, the [Pt(Oct-dtc)(bpy)]NO₃ and [Pd(Oct-dtc)(bpy)]NO₃ complexes can bind CT-DNA taking the mode of intercalation. This mode of binding supports the above three hypotheses.

Using the CT-DNA denaturation plots (Figure 2) and Pace method [50], the value of $K$, that is, unfolding equilibrium constant and $\Delta G^\circ$, unfolding free energy of CT-DNA, at two temperatures of 300 K and at 310 K in the presence of Pt(II) and Pd(II) complexes have been calculated. In this method, Pace had assumed two-state mechanism, nature and denature, and then calculated unfolding free energy of DNA, that is, $\Delta G^\circ$ by using (1):

$$K = \frac{A_N - A_{obs}}{A_{obs} - A_D},$$

$$\Delta G^\circ = -RT \ln K,$$

where $A_{obs}$ is absorbance readings in transition region and $A_N$ and $A_D$ are absorbance readings of nature and denatured conformation of DNA, respectively. A straight line is observed when the values of $\Delta G^\circ$ are plotted against the concentrations of each metal complex in the transition region at 300 K and at 310 K. These plots are shown in Figure 3 for Pt(II) complex and the inset for Pd(II) complex. The equation for these lines can be written as follow [51]:

$$\Delta G^\circ = \Delta G_{(H_2O)}^\circ - m[\text{complex}].$$

Here, the values of $\Delta G_{(H_2O)}^\circ$ for each curve are measured from the intercept on ordinate of the plots and it is conformational stability of DNA in the absence of metal complex. $m$ (the slope of each curve in the same plots) is a measure of the metal complex ability to denature CT-DNA and is summarized in Table 1. The values of $m$ for the above complexes are much higher than those of Pt(II) and Pd(II) complexes reported earlier [15–17], which indicate the higher ability of this Pt(II) and Pd(II) complexes to denature CT-DNA. As we know, the higher the values of $\Delta G^\circ$, the larger the conformational stability of CT-DNA. However, the values of $\Delta G^\circ$ (Table 1) are decreased by increasing the temperature. This is as expected because, in general, the decrease in $\Delta G_{(H_2O)}^\circ$ value is the main reason for the decrease in CT-DNA stability [52]. Molar enthalpy...
Table 1: Thermodynamic parameters of CT-DNA denaturation by palladium(II) and platinum(II) complexes.

| Compound                  | Temperature (K) | \(a m\) (kJ/mol) (mmol/L) \(^{-1}\) | \(b \Delta G\)\(_{\text{H}_2\text{O}}\) (kJ/mol) | \(c \Delta H\)\(_{\text{H}_2\text{O}}\) (kJ/mol) | \(d \Delta S\)\(_{\text{H}_2\text{O}}\) (kJ/mol) |
|----------------------------|-----------------|------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| [Pt(bpy)(Oct-dtc)]NO\(_3\) | 300             | 123                                | 8.30                                          | 34.5                                          | 0.08                                          |
|                            | 310             | 133                                | 7.40                                          |                                               |                                               |
| [Pd(bpy)(Oct-dtc)]NO\(_3\) | 300             | 195                                | 13.44                                         | 28.09                                         | 0.05                                          |
|                            | 310             | 218                                | 12.93                                         |                                               |                                               |

\(a\) Measure of the metal complex ability to denature CT-DNA.

\(b\) Conformational stability of CT-DNA in the absence of metal complex.

\(c\) The heat needed for CT-DNA denaturation in the absence of metal complex.

\(d\) The entropy of CT-DNA denaturation by metal complex.

Figure 3: The molar Gibbs free energies of unfolding (\(\Delta G\) \(_{\text{con}}\) versus \([L]\)) of CT-DNA in the presence of [Pt(bpy)(Oct-dtc)]NO\(_3\) and the inset for [Pd(bpy)(Oct-dtc)]NO\(_3\) complexes.

Figure 4: The molar enthalpies of CT-DNA denaturation in the interaction with [Pt(bpy)(Oct-dtc)]NO\(_3\) and the inset for [Pd(bpy)(Oct-dtc)]NO\(_3\) complexes in the range of 300 K to 310 K.

of CT-DNA denaturation in absence of Pt(II) and Pd(II) complexes, \(\Delta H\)\(_{\text{H}_2\text{O}}\), is another important thermodynamic parameter. To find this, we calculated the molar enthalpy of CT-DNA denaturation in presence of the metal complexes, \(\Delta H\)\(_{\text{conformation}}\) or \(\Delta H\)\(_{\text{denaturation}}\), in the range of two temperatures using Gibbs-Helmholtz equation [53]. On plotting the values of these enthalpies versus the concentration of metal complexes, straight lines will be obtained which are shown in Figure 4 for [Pt(Oct-dtc)(bpy)]NO\(_3\) and the inset for [Pd(Oct-dtc)(bpy)]NO\(_3\) complexes. Extrapolation of these lines (intercept on ordinate, i.e., absence of metal complexes) gives the values of \(\Delta H\)\(_{\text{H}_2\text{O}}\) (Table 1). The above thermodynamic parameters agree well with those we have reported for [Pt/Pd(bpy)(Et-dtc)]NO\(_3\) [15] and [Pt/Pd(bpy)(Bu-dtc)]NO\(_3\) [16] complexes.

3.2.2. UV-Vis Spectral Studies and Evaluation of Binding Parameters. A fixed amount of [Pt(Oct-dtc)(bpy)]NO\(_3\) and [Pd(Oct-dtc)(bpy)]NO\(_3\) complexes (0.006 mM for Pt(II) complex and 0.025 mM and 0.037 mM for Pd(II) complex at 300 K and 310 K, resp.) was titrated with increasing amounts of CT-DNA (0.010 mM to 0.081 mM and 0.010 mM to 0.076 mM for Pt(II) complex and 0.024 mM to 0.089 mM and 0.061 to 0.114 mM for Pd(II) complex at 300 K and 310 K, resp.). In this experiment, the changes in the absorbance, \(\Delta A\), of metal complexes at 321 nm for Pt(II) complex and 305 nm for Pd(II) complex were calculated by subtracting the absorbance reading of DNA-metal complexes solution from absorbance reading of free metal complexes solution. The maximum \(\Delta A\) (\(\Delta A_{\text{max}}\)), that is, change in the absorbance when all binding sites on CT-DNA were occupied by metal complex (Figure 5, intercept on ordinate) is 0.021 and 0.028 for Pt(II) complex and 0.035 and 0.058 for Pd(II) complex at 300 K and 310 K, respectively. These values of \(\Delta A_{\text{max}}\) were used to calculate the concentration of bound metal complexes to CT-DNA in the next experiment: a fixed amount of CT-DNA (0.023 mM...
for [Pd(bpy)(Oct-dtc)]NO₃.

observed [15, 55].

binding of analogous complexes with CT-DNA has also been suggesting cooperative binding [54]. Similar cooperativity in

(Figure 6). These plots are curvilinear concave downwards,

concentrations of metal complexes bound to CT-DNA, [Pt(II) complex at 300 K and 310 K, resp.). Now, the complex and 0.017 to 0.022 mM and 0.018 to 0.022 mM complexes (10 to 0.025 mM and 0.002 to 0.020 mM for Pt(II) and Pd(II) titrated with varying concentrations of Pt(II) and Pd(II) for Pt(II) complex and 0.001 mM for Pd(II) complex) was

Figure 5: The changes in the absorbance of fixed amount of each metal complex in the interaction with varying amount of CT-DNA at 300 K and 310 K. The linear plot of the reciprocal of [DNA] for [Pt(bpy)(Oct-dtc)]NO₃ and the inset for [Pd(bpy)(Oct-dtc)]NO₃ to CT-DNA.

Figure 6: Scatchard plots for binding of [Pt(bpy)(Oct-dtc)]NO₃ and the inset for [Pd(bpy)(Oct-dtc)]NO₃ to CT-DNA.

On substituting the above experimental data (ν and [L]ₗ) in Hill equation,

\[
ν = \frac{g(K[L]_f)^n}{(1 + (K[L]_f)^n)},
\]

we get a series of equations with unknown binding parameters n, K, and g. Using Eureka software, the theoretical values of these parameters have been deduced. The results are shown in Table 2. These results are comparable with those of 2,2’-bipyridine-platinum and -palladium complexes of dithiocarbamates as reported earlier [15, 16]. The apparent binding constants of two complexes obtained were 4.01 × 10⁴ M⁻¹ at 300 K and 1.10 × 10⁴ M⁻¹ at 310 K for Pt(II) complex and 0.017 to 0.022 mM and 0.018 to 0.022 mM for Pt(II) complex at 300 K and 310 K, resp.). Now, the concentrations of metal complexes bound to CT-DNA, [L]ₗ, and the concentration of free metal complex, [L]ₗ, are calculated using the relationship

\[
[L]_b = \frac{ΔA}{[L]_f/ΔA_{max}},
\]

\[
[L]_f = [L]_b - [L]_b,
\]

where [L]ₗ is the maximum concentration of metal complex added to saturate all the binding sites of CT-DNA. The Scatchard plots were obtained separately at 300 K and 310 K by plotting ν/[L] versus ν of the relationship ν = [L]ₗ/[DNA], (Figure 6). These plots are curvilinear concave downwards, suggesting cooperative binding [54]. Similar cooperativity in binding of analogous complexes with CT-DNA has also been observed [15, 55].

| Compound | Temperature (K) | ΔA_{max} (10⁻⁴) | b | c(K × 10⁻⁴ M⁻¹) | d(n) | eError |
|----------|---------------|-----------------|---|----------------|------|-------|
| [Pt(bpy)(Oct-dtc)]NO₃ | 300 | 0.021 | 6 | 4.01 | 1.87 | 0.005 |
| | 310 | 0.028 | 6 | 1.10 | 1.36 | 0.007 |
| [Pd(bpy)(Oct-dtc)]NO₃ | 300 | 0.035 | 6 | 5.28 | 5.92 | 0.13 |
| | 310 | 0.058 | 6 | 5.86 | 6.18 | 0.14 |

*Change in the absorbance when all the binding sites on CT-DNA were occupied by metal complex.

*The number of binding sites per 1000 nucleotides.

*The apparent binding constant.

*The Hill coefficient (as a criterion of cooperativity).

*Maximum error between theoretical and experimental values of ν.
suggests that CT-DNA has not separated from the metal peak obtained for the two wavelengths are not resolved and the inset for Pd(II) complex. This plot shows that the system. These results are given in Figure 9 for Pt(II) complex monitored at 321 nm and 260 nm for DNA-Pt(II) complex and at 305 nm and 260 nm for DNA-Pd(II) complex.

These results are given in Figure 9 for Pt(II) complex monitored at 321 nm and 260 nm for DNA-Pt(II) complex and at 305 nm and 260 nm for DNA-Pd(II) complex. These results are given in Figure 9 for Pt(II) complex monitored at 321 nm and 260 nm for DNA-Pt(II) complex and at 305 nm and 260 nm for DNA-Pd(II) complex. Thus, it implies that the binding between CT-DNA and the metal complexes is not reversible under such circumstances. This is due to the fact that if the interaction between CT-DNA and metal complexes was weak, the CT-DNA should have come out of the column separately [63].

3.3. Gel Filtration. [Pt(Oct-dtc)(bpy)]NO₃ and [Pd(Oct-dtc)(bpy)]NO₃ complexes (0.125 mM and 0.050 mM, resp.) were incubated with CT-DNA (0.223 mM for Pt(II) complex and 0.249 mM for Pd(II) complex) for 6 h at 300 K in Tris-HCl buffer, pH 7.0. DNA-metal complexes were then passed through a Sephadex G-25 column equilibrated with the same buffer. The elution of the column fraction of 2.0 mL was monitored at 321 nm and 260 nm for DNA-Pt(II) complex system and at 305 nm and 260 nm for DNA-Pd(II) complex system. These results are given in Figure 9 for Pt(II) complex and the inset for Pd(II) complex. This plot shows that the peak obtained for the two wavelengths are not resolved and suggests that CT-DNA has not separated from the metal complexes. Thus, it implies that the binding between CT-DNA and the metal complexes is not reversible under such circumstances. This is due to the fact that if the interaction between CT-DNA and metal complexes was weak, the CT-DNA should have come out of the column separately [63].

4. Conclusions

The above work describes the synthesis, characterization, and cytotoxic studies of a novel and water-soluble platinum(II) and palladium(II) complexes possessing a planar aromatic ligand for intercalation and a dithiocarbamate ligand to avoid its renal damage. Ic₅₀ values of these complexes are much lower than those of cisplatin. Furthermore, detailed interaction studies of the complexes with CT-DNA have been carried out. They cooperatively bind to DNA through intercalation mode and unexpectedly denature DNA at extremely low concentration. Determinations of several binding and thermodynamic parameters have also been attempted. They
Table 3: Binding parameters for the effect of platinum and palladium complexes on the fluorescence of EBr in the presence of CT-DNA.

| Compound                        | $r_f$ | $K \times 10^4$ (M)$^{-1}$ | $n$  |
|---------------------------------|-------|-----------------------------|------|
| [Pt/Pd(bpy)(Oct-dtc)]NO$_3$     | 0.00  | 1.68                        |      |
|                                 | 0.55  | 1.04                        |      |
| [Pt(bpy)(Oct-dtc)]NO$_3$        | 1.185 | 0.72                        |      |
|                                 | 1.85  | 0.55                        |      |
|                                 | 0.2   | 1.08                        |      |
| [Pd(bpy)(Oct-dtc)]NO$_3$        | 0.58  | 0.78                        | 0.0078|
|                                 | 0.92  | 0.56                        |      |

Formal ratio of metal complex to nucleotide concentration.

Association constant.

Number of binding sites ($n$) per nucleotide.

Figure 10: Fluorescence emission spectra of interacted EB-DNA in the absence (1) and presence of different concentrations of [Pt(bpy)(Oct-dtc)]NO$_3$ and the inset for [Pd(bpy)(Oct-dtc)]NO$_3$: 33 μM (2), 71 μM (3), and 111 μM (4) and 12 μM (2), 35 μM (3), and 55 μM (4), respectively, at 300 K.

may be helpful to understand the mechanism of the interaction between these complex and nucleic acid that must be quite different from that of cisplatin.

4.1. Competitive Binding between Ethidium Bromide (EB) and Pt(II)/Pd(II) Complexes for CT-DNA. No fluorescence was observed for aqueous solution of above Pt(II) and Pd(II) complexes alone or in the presence of calf thymus DNA. So, the binding of Pt(II) and Pd(II) complexes with CT-DNA cannot be directly presented in the emission spectra. It has been studied by competitive EB binding experiments [64, 65]. The fluorescence of EB is greatly enhanced upon intercalation to DNA. The effect of platinum(II)-2,2′-bipyridine and palladium(II)-2,2′-bipyridine complexes of octylthiocarbamate on the fluorescence intensity of DNA-EB complexes was studied to get the mode of their binding to CT-DNA. Figure 10 shows the effect of Pt(II) and Pd(II) complexes (33 μM, 71 μM and 111 μM for Pt(II) complex and 12 μM, 35 μM and 55 μM for Pd(II) complex) on fluorescence spectrum of solution containing CT-DNA (60 μM) and EB (2 μM). It is seen that increasing the concentration of the Pt(II)/Pd(II) complexes results in a gradual decrease in fluorescence intensity of DNA-EB solution, without effecting any perceptible shifts in fluorescence $\lambda_{max}$. It further proves the interaction between these complex and DNA molecules. A similar fluorescence quenching behavior was observed for analogous Pt(II)/Pd(II) complexes reported earlier [47, 48].

Further studies to characterize the mode of binding of [Pt(Oct-dtc)(bpy)]NO$_3$ and [Pd(Oct-dtc)(bpy)]NO$_3$ to DNA were carried out [66, 67]. The number of EB molecules intercalated to CT-DNA in presence of different concentrations of the Pt(II) complex and Pd(II) complex was calculated using Scatchard analysis [68]. In this experiment, the wavelengths of excitation and emission were set at 540 nm and 700 nm, respectively, with both having 0.5 nm slit widths. Solutions of CT-DNA, EB, and metal complexes were prepared in Tris-HCl buffer of pH 7.0. In this medium-solutions of Pt(II) complex and Pd(II) complex were intercalated with CT-DNA by incubating them at 300 K and 310 K for 6 h; appropriate amount of EB was added to them and further incubated at room temperature (300 K) for 6 h and finally processed for fluorescence spectral measurement. Saturation curves of fluorescence intensity for [Pt/Pd(Oct-dtc)(bpy)]$^+$-DNA systems at different $r_f$ values (0.55, 1.18, and 1.85 for Pt(II) complex and 0.2, 0.58 and 0.92 for Pd(II) complex) in presence of increasing concentrations of EB (2, 4, 8, 16, 20 μM) were obtained. The fluorescence Scatchard plots obtained for binding of EB to CT-DNA in absence (♦) and presence (◇, Δ, and ○) of various concentration of Pt(II) and Pd(II) (inset) complexes were shown in Figure 11. This figure shows that the complexes inhibit competitively the EB binding to CT-DNA (type A behavior) [68], where number of binding sites $n$ (intercept on the abscissa) remains constant and the slope of the graphs that is $K_{app}$ (apparent association constant) decreases with increasing the concentrations of Pt(II) and Pd(II) complexes (Table 3). This implies that the [Pt/Pd(Oct-dtc)(bpy)]NO$_3$ complexes are intercalating in CT-DNA and thereby competing for intercalation sites occupied by EB. The values of $K_{app}$ and $n$, the number of binding sites per nucleotide, are listed in Table 3. These data suggested that the interaction of the [Pd(Oct-dtc)(bpy)]NO$_3$ complex with CT-DNA was stronger than that of [Pt(Oct-dtc)(bpy)]NO$_3$ complex, which were consistent with the above absorption spectral results. Compare their $K_{app}$ values with those of other known CT-DNA-intercalative complexes which possess analogical structure; the Pd(II) complexes in
our paper have similar or stronger affinities with CT-DNA [17]. Similar modes of binding seem to be involved in other complexes [52, 69].

Acknowledgments

The support of this work by the University of Sistan and Baluchestan and the University of Tehran is gratefully acknowledged.

References

[1] S. D. Cummings and R. Eisenberg, “Luminescent platinum(II) complexes of quinoxaline-2,3-dithiolate,” Inorganic Chemistry, vol. 34, no. 8, pp. 2007–2014, 1995.

[2] C. Makedonas and C. A. Mitsopoulou, “Tuning the properties of M(diimine)(dithiolate) complexes—The role of the metal and solvent effect. A combined experimental, DFT and TD-DFT study,” Inorganica Chimica Acta, vol. 360, no. 14, pp. 3997–4009, 2007.

[3] C. Makedonas, C. A. Mitsopoulou, F. J. Lahoz, and A. I. Balana, “Synthesis, characterization, and crystal structure of the Pd(phen)(bdt) complex. A DFT and TD-DFT study of its ground electronic and excited states compared to those of analogous complexes,” Inorganic Chemistry, vol. 42, no. 26, pp. 8853–8865, 2003.

[4] C. Makedonas and C. A. Mitsopoulou, “An investigation of the reactivity of [(diimine)(dithiolato)M] complexes using the Fukui functions concept,” European Journal of Inorganic Chemistry, no. 3, pp. 590–598, 2006.

[5] A. Pasini, G. D. Alfonso, C. Manzotti, M. Moret, S. Spinelli, and M. Valsecchi, “Cytotoxic diamine-platinum(II) complexes with methylsulfanyl carboxylates as the leaving groups. Synthesis, characterization, and reactivity toward chloride ions, 5′-GMP, and 9-methylguanine,” Inorganic Chemistry, vol. 33, no. 18, pp. 4140–4148, 1994.

[6] M. A. Zemaitis and F. E. Greene, “In vivo and in vitro effects of thiuram disulfides and dithiocarbamates on hepatic microsomal drug metabolism in the rat,” Toxicology and Applied Pharmacology, vol. 48, no. 2, pp. 343–350, 1979.

[7] R. Mital, N. Jain, and T. S. Srivastava, “Synthesis, characterization and cytotoxic studies of diamine and diimine palladium(II) complexes of diethylthiocarbamate and binding of these and analogous platinum(II) complexes with DNA,” Inorganica Chimica Acta, vol. 166, no. 1, pp. 135–140, 1989.

[8] N. Manav, A. K. Mishra, and N. K. Kaushik, “In vitro antitumour and antibacterial studies of some Pt(IV) dithiocarbamate complexes,” Spectrochimica Acta Part A, vol. 65, no. 1, pp. 32–35, 2006.

[9] G. Faraglia, S. Sitran, and D. Montagner, “Pyrrolidine dithiocarbamates of Pd(II),” Inorganica Chimica Acta, vol. 358, no. 4, pp. 971–980, 2005.

[10] N. Jain and T. S. Srivastava, “Synthesis and spectroscopic studies of some diamine platinum(II) complexes of diethylthiocarbamate,” Inorganica Chimica Acta, vol. 128, no. 2, pp. 151–153, 1987.

[11] C. Metcalfe and J. A. Thomas, “Kinetically inert transition metal complexes that reversibly bind to DNA,” Chemical Society Reviews, vol. 32, pp. 215–224, 2003.

[12] X. W. Liu, J. Li, H. Li, K. C. Zheng, H. Chao, and L. N. Ji, “Synthesis, characterization, DNA-binding and photocleavage of complexes [Ru(phen)2(6-OH-dppz)]2+ and [Ru(phen)2(6-NO2-dppz)]2+,” Journal of Inorganic Biochemistry, vol. 99, no. 12, pp. 2372–2380, 2005.

[13] M. Gay, A. M. Montana, V. Moreno, M. J. Prieto, J. M. Perez, and C. Alonso, “Studies of interaction of trichloro-2-cis-N,N-dimethyl-1-[6-(N,N-dimethyl-ammoniummethyl)-cyclohex-3-ene-1-yl]-methylammoniumplatinum(II) chloride with DNA: effects on secondary and tertiary structures of DNA. Cytotoxic assays on human ovarian cancer cell lines, resistant and non-resistant to cisplatin,” Bioorganic and Medicinal Chemistry, vol. 14, no. 5, pp. 1565–1572, 2006.

[14] E. Gao, M. Zhu, H. Yin, L. Liu, Q. Wu, and Y. Sun, “Synthesis, characterization, interaction with DNA and cytotoxicity in vitro of dinuclear Pd(II) and Pt(II) complexes dibridged by 2,2′-azanediyldibenzonic acid,” Journal of Inorganic Biochemistry, vol. 102, no. 10, pp. 1958–1964, 2008.

[15] H. Mansouri-Torshizi, M. I. Moghaddam, A. Divsalar, and A. A. Saboury, “2,2′-Bipyridinebutyldithiocarbamato platinum(II) and palladium(II) complexes: synthesis, characterization, cytotoxicity and rich DNA-binding studies,” Bioorganic and Medicinal Chemistry, vol. 16, no. 21, pp. 9616–9625, 2008.

[16] M. I. Moghaddam, H. Mansouri-Torshizi, A. Divsalar, and A. A. Saboury, “Synthesis, characterization, cytotoxic and DNA binding studies of diimine platinum(II) and palladium(II) complexes of short hydrocarbon chain ethyldithiocarbamate ligand,” Journal of the Iranian Chemical Society, vol. 6, no. 3, pp. 552–569, 2009.

[17] H. Mansouri-Torshizi, M. I. Moghaddam, A. Divsalar, and A. A. Saboury, “Diimine platinum(II) and palladium(II) complexes of dithiocarbamate derivative as potential antitumor agents: synthesis, characterization, cytotoxicity, and detail DNA-binding studies,” Journal of Biomolecular Structure and Dynamics, vol. 26, no. 5, pp. 575–586, 2009.

[18] M. Saeidfar, H. Masouri-Torshizi, G. R. Behbehani, A. A. Saboury, and A. Divsalar, “A Thermodynamic study of new
designed complex of ethylenediamine 8-hydroxyquinolinato palladium(II) chloride with calf thymus DNA,” Bulletin of the Korean Chemical Society, vol. 30, no. 9, pp. 1951–1955, 2009.

[19] L. Ronconi, C. Maccato, D. Barreca, R. Saini, M. Zancato, and D. Fregona, “Gold(III) dithiocarbamate derivatives of N-methylglycine: an experimental and theoretical investigation,” Polyhedron, vol. 24, no. 4, pp. 521–531, 2005.

[20] L. Ronconi, L. Giovagnini, C. Marzano et al., “Gold dithiocarbamate derivatives as potential antineoplastic agents: design, spectroscopic properties, and in vitro antitumor activity,” Inorganic Chemistry, vol. 44, no. 6, pp. 1867–1881, 2005.

[21] K. Unoura, A. Yamazaki, A. Nagasawa et al., “Substituent effects of cis-dioxobis(dithiocarbamato) molybdenum(VI) on redox potentials for one-electron reduction and second-order rate constants for oxygen atom transfer,” Inorganic Chemistry, vol. 269, no. 2, pp. 260–268, 1998.

[22] H. Teruel, Y. C. Gorrin, and L. R. Falvello, “Bis(N-pyrollidinedithiocarbamate)dioxomolybdenum(VI): synthesis, structure and reactivity,” Inorganic Chimica Acta, vol. 316, no. 1-2, pp. 1–6, 2001.

[23] H. Zheng, W. H. Leung, J. L. C. Chim et al., “Heterobimetallic μ-nitrido complexes containing ruthenium(II) dithiocarbamate,” Inorganica Chimica Acta, vol. 306, no. 2, pp. 184–192, 2000.

[24] B. Neeleam, R. M. Mannar, N. Fehmida, B. Alok, B. Sudha, and A. Amir, “Palladium(II) complexes of NS donor ligands derived from S-methyl- dithiocarbazate, S-benzylidithiocarbazate and thiosemicarbazide as antiamoebic agents,” European Journal of Medicinal Chemistry, vol. 35, no. 5, pp. 481–486, 2000.

[25] A. Martinez, J. Lorenzo, M. I. Prieto et al., “Influence of the position of substituents in the cytotoxic activity of trans platinum complexes with hydroxymethyl pyridines,” Bioorganic and Medicinal Chemistry, vol. 15, no. 2, pp. 969–979, 2007.

[26] F. Shaheen, A. Badshah, M. Gielen et al., “Synthesis, characterization, antibacterial and cytotoxic activity of new palladium(II) complexes with dithiocarbamate ligands: X-ray structure of bis(dibenzyl-1-S:S'-dithiocarbamato)Pd(II),” Journal of Organometallic Chemistry, vol. 692, no. 14, pp. 3019–3026, 2007.

[27] N. Manav, A. K. Mishra, and N. K. Kaushik, “Triphenyl phosphine adducts of platinum(IV) and palladium(II) dithiocarbamates complexes: a spectral and in vitro study,” Spectrochimica Acta Part A, vol. 60, no. 13, pp. 3087–3092, 2004.

[28] D. Fregona, L. Giovagnini, L. Ronconi et al., “Pt(II) and Pd(II) derivatives of ter-butylsarcosinedithiocarbamate: synthesis, chemical and biological characterization and in vitro nephrotoxicity,” Journal of Inorganic Biochemistry, vol. 93, no. 3-4, pp. 181–189, 2003.

[29] V. Alverdi, L. Giovagnini, C. Marzano et al., “Characterization studies and cytotoxicity assays of Pt(II) and Pd(II) dithiocarbamate complexes by means of FT-IR, NMR spectroscopy and mass spectrometry,” Journal of Inorganic Biochemistry, vol. 98, no. 6, pp. 1117–1128, 2004.

[30] G. Faraglia, D. Fregona, S. Sitran et al., “Platinum(II) and palladium(II) complexes with dithiocarbamates and amines: synthesis, characterization and cell assay,” Journal of Inorganic Biochemistry, vol. 83, no. 1, pp. 31–40, 2001.

[31] J. Landi, M. P. Hacker, and N. Farrell, “Sulfoxides as leaving groups. Effect of sterically hindered aliphatic sulfoxides on the antitumor activity of chloro(substituted sulfoxide)(1,1-diaminomethylcyclohexane)platinum(II) nitate,” Inorganica Chimica Acta, vol. 202, no. 1, pp. 79–83, 1992.

[32] E. C. H. Ling, G. W. Allen, and T. W. Hambley, “The prepa- ration and characterisation of some aminesulfoxidedichloro- platinum(II) complexes,” Journal of the Chemical Society, Dalton Transactions, no. 24, pp. 3705–3710, 1993.

[33] H. Mansouri-Torshizi, T. S. Srivastava, S. J. Chavan, and M. P. Chitnis, “Cytotoxicity and DNA Binding Studies of Several Platinum(II) and Palladium(II) Complexes of 2,2’-Bipyridine and an Anion of 2-Pyrinedicarboxylic/2-Pyrazincarboxylic Acid,” Journal of Inorganic Biochemistry, vol. 48, pp. 63–70, 1992.

[34] F. A. Palocsay and J. V. Rund, “Reaction between 1,10- phenanthroline and platinum(II) compounds. I. Reaction in aqueous solution,” Inorganic Chemistry, vol. 8, no. 3, pp. 524–528, 1969.

[35] S. Bi, H. Zhang, C. Qiao, Y. Sun, and C. Liu, “Studies of interaction of emodin and DNA in the presence of ethidium bromide by spectroscopic method,” Spectrochimica Acta Part A, vol. 69, no. 1, pp. 123–129, 2008.

[36] J. Marmur, “A procedure for the isolation of deoxyribonucleic acid from micro-organisms,” Journal of Molecular Biology, vol. 3, no. 2, pp. 208–218, 1961.

[37] R. S. Kumar and S. Arunachalam, “Synthesis, characterization and DNA binding studies of a polymer-cobalt(III) complex containing the 2,2’-bipyridyl ligand,” Polyhedron, vol. 25, no. 16, pp. 3113–3117, 2006.

[38] A. Manohar, K. Ramalingam, G. Bocelli, and L. Righi, “Synthesis, spectral and cyclic voltammetric studies on (4,4’-bi- pyridyl)bis(di(2-hydroxyethyl)dithiocarbamato)zinc(II) and (4,4’-bipyridyl)bis(N-methyl, N-ethanoldithiocarbama- to)zinc(II) and their X-ray crystal structures,” Inorganica Chimica Acta, vol. 314, no. 1-2, pp. 177–183, 2001.

[39] L. Kumar, N. R. Kandasamy, T. S. Srivastava, A. J. Amokar, M. K. Adwankar, and M. P. Chitnis, “Synthesis and spectroscopic studies of potential anticancer [platinum(II)(2,2’- bipyridine)(amino acid)]n+ (n = 1 or 2) complexes,” Journal of Inorganic Biochemistry, vol. 23, no. 1, pp. 1–11, 1984.

[40] H. Mansouri-Torshizi, M. Saedifar, A. Divsalar, and A. A. Saboury, “Study on Interaction of DNA from Call Thymus with 1,10-phenanthrolinehexyldithiocarbamatopalladium(II) nitate as Potential Antitumor Agent,” Journal of Biomolecular Structure & Dynamics, vol. 28, no. 5, pp. 805–814, 2011.

[41] W. J. Geary, “The use of conductivity measurements in organic solvents for the characterisation of coordination compounds,” Coordination Chemistry Reviews, vol. 7, no. 1, pp. 81–122, 1971.

[42] F. M. Freimoser, C. A. Jakob, M. Aebi, and U. Tuor, “The MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay is a fast and reliable method for colorimetric determination of fungal cell densities,” Applied and Environmental Microbiology, vol. 65, no. 8, pp. 3727–3729, 1999.

[43] J. M. Kelly, A. B. Tossi, D. J. Mcconnell, and C. Ohuigin, “A study of the interactions of some poly(pyridyl)ruthenium(II) complexes with DNA using fluorescence spectroscopy, topos- somerisation and thermal denaturation,” Nucleic Acids Research, vol. 13, no. 17, pp. 6017–6034, 1985.

[44] R. S. Kumar, S. Arunachalam, V. S. Periasamy, C. P. Preethy, A. Riasdeen, and M. A. Akbarsha, “Surfactant-cobalt(III) complexes: synthesis, critical micelle concentration (CMC) determination, DNA binding, antimicrobial and cytotoxicity
R. F. Greene and C. N. Pace, "Urea and guanidine hydrochloride: studies," *Journal of Inorganic Biochemistry*, vol. 103, no. 1, pp. 117–127, 2009.

[55] U. Chaveerach, A. Meenongwa, Y. Trongpanich, C. Soikum, and P. Chaveerach, "DNA binding and cleavage behaviors of copper(II) complexes with amido-O-methylurea and N-methylphenyl-amidino-O-methylurea, and their antibacterial activities," *Polyhedron*, vol. 29, no. 2, pp. 731–738, 2010.

[56] F. Arjmand and F. Sayeed, "Synthesis, characterization and DNA-binding studies of mono and heterobimetallic complexes Cu[ single bond ]Sn2/Zn[ single bond ]Sn2 and their DNA cleavage activity," *Journal of Molecular Structure*, vol. 965, no. 1–3, pp. 14–22, 2010.

[57] H. Mansouri-Torshizi, M. Saeidifar, A. Divsalar, and A. A. Saboury, "Interaction studies between a 1,10-phenanthroline adduct of palladium(II) dithiocarbamate anti-tumor complex and calf thymus DNA. A synthesis spectral and in-vitro study," *Spectrochimica Acta Part A*, vol. 77, no. 1, pp. 312–318, 2010.

[58] H. Mansouri-Torshizi, M. Saeidifar, A. Divsalar, A. A. Saboury, and S. Shahraei, "Interaction studies of a novel, water-soluble and anti-cancer palladim(II) complex with calf thymus DNA," *Bulletin of the Korean Chemical Society*, vol. 31, no. 2, pp. 435–441, 2010.

[59] M. P. Hacker, E. B. Double, and I. H. Krakoff, *Platinum Coordination Complexes in Cancer Chemotherapy*, Martinus Nijhoff, Boston, Mass, USA, 1984.

[60] R. F. Greene and C. N. Pace, "Urea and guanidine hydrochloride denaturation of ribonuclease, lysozyme, α-amylase polymerase, " *Biochemical Journal*, vol. 249, no. 17, pp. 5388–5393, 1974.

[61] A. M. Q. King and B. H. Nicholson, "The interaction of allatoxin B1 with polynucleotides and its effect on ribonucleic acid polymerase," *Biochemical Journal*, vol. 114, no. 4, pp. 679–687, 1969.

[62] S. Z. Bathaie, A. Bolhasani, R. Hoshyar, B. Ranjbar, F. Sabouni, and A. A. Moosavi-Movahedi, "Interaction of saffron carotenoids as anticancer compounds with ctDNA, oligo (dG.dC)15, and oligo (dA.dT)15, " *Carotenoids as Anticancer Compounds with ctDNA, oligo (dA.dT)15, and oligo (dG.dC)15, Biochemical Journal*, vol. 114, no. 4, pp. 679–687, 1969.

[63] M. N. Patel, P. A. Parmar, and D. S. Gandhi, "Square pyramidal copper(II) complexes with fourth generation fluoroquinolone and neutral bidentate ligand: structure, antibacterial, SOD mimic and DNA-interaction studies," *Bioorganic and Medicinal Chemistry*, vol. 18, no. 3, pp. 1227–1235, 2010.

[64] Q. Wang, Z. Yang, G. Qi, and D. Qin, "Synthesis, crystal structure, antioxidant activities and DNA-binding studies of the Ln(III) complexes with 7-methoxycoumarin-3-carbaldehyde-(4'-hydroxy) benzoyl hydrazone," *European Journal of Medicinal Chemistry*, vol. 44, no. 6, pp. 2425–2433, 2009.